A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report(†)

BACKGROUND: A phase I trial of veliparib (ABT-888), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, and temozolomide (TMZ) was conducted in children with recurrent brain tumors to (i) estimate the maximum tolerated doses (MTDs) or recommended phase II doses (RP2Ds) of veliparib and TMZ; (ii) d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Su, Jack M., Thompson, Patrick, Adesina, Adekunle, Li, Xiao-Nan, Kilburn, Lindsay, Onar-Thomas, Arzu, Kocak, Mehmet, Chyla, Brenda, McKeegan, Evelyn, Warren, Katherine E., Goldman, Stewart, Pollack, Ian F., Fouladi, Maryam, Chen, Alice, Giranda, Vincent, Boyett, James, Kun, Larry, Blaney, Susan M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2014
Schlagworte:
Pediatric Neuro-Oncology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4232081/
https://ncbi.nlm.nih.gov/pubmed/24908656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou103
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge